This pilot clinical trial studies whether fluorine F 18 fluorothymidine (FLT) will enable positron emission tomography/magnetic resonance imaging (PET/MRI) to measure response earlier in patients with metastatic solid tumors who are receiving treatment with agents that reduce the growth of new blood vessels. Diagnostic procedures, such as FLT-PET/MRI, are used to measure a patient's response to earlier treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02055586.
PRIMARY OBJECTIVES:
I. To determine the feasibility of FLT-PET/MR imaging for early prediction of treatment response in patients undergoing anti-angiogenic cancer treatment.
II. To assess the test-retest reproducibility of PET biomarker (FLT) uptake using PET/MRI.
III. To assess the test-retest reproducibility of quantification of MR sequences (multi-parametric MRI particularly related to tissue perfusion).
IV. To assess the ability of PET/MRI to measure changes in PET biomarker (FLT) tumor uptake after initiation of therapy.
V. To assess changes in qualitative morphologic imaging and quantitative functional MRI parameters after initiation of therapy.
SECONDARY OBJECTIVES:
I. To compare early changes in PET biomarker (FLT) tumor uptake with treatment response assessed at completion of therapy (prediction of treatment response).
II. To compare changes in MRI signal intensities (multi-parametric MRI) with treatment response assessed at completion of therapy.
III. To compare results from multi-parametric MR imaging with FLT tumor uptake.
IV. To assess combinations of quantitative PET and MRI metrics.
OUTLINE:
Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationCase Comprehensive Cancer Center
Principal InvestigatorNorbert Avril
